Mirikizumab - Subcutaneous (SC)

DRUG3 trials

Sponsors

University of North Carolina, Chapel Hill, Eli Lilly and Company

Conditions

Colitis, UlcerativeCrohn DiseasePouch, IlealPouches, IleoanalPouchitis

Phase 2

A Master Protocol (IIBD): A Study of Multiple Drugs in Adults With Ulcerative Colitis or Crohn's Disease

RecruitingNCT07483073

Eli Lilly and CompanyColitis, Ulcerative, Crohn Disease

Start: 2026-05-04End: 2028-03-01Target: 60Updated: 2026-09-08

A Study of LY4395089 and Mirikizumab (LY3074828) Given Together and Mirikizumab (Alone) in Adults With Crohn's Disease

RecruitingNCT07483099

Eli Lilly and CompanyCrohn Disease

Start: 2026-05-04End: 2028-03-01Target: 60Updated: 2026-09-08

Phase 4

Mirikizumab in the Treatment of Chronic Inflammatory Conditions of the Pouch

RecruitingNCT06864403

University of North Carolina, Chapel HillPouches, Ileoanal, Pouch, Ileal, Pouchitis

Start: 2025-08-12End: 2027-04-01Target: 25Updated: 2026-01-30